Clinical Trial Update: Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism [Phase 1]

View source ↗

Summary

Phase 1 Yale trial examined the effects of NMDA receptor antagonism in schizophrenia, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Yale University | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED